Celgene Corporation (NASDAQ:CELG) Stock Trading Up

760

Dallas, Texas 11/04/2013 (Financialstrend) – In Friday’s trading, Celgene Corporation (NASDAQ:CELG) rose by 1.90%. The opening price of the shares was $149.27, which climbed to an intraday high of $151.45 and dipped to a close of $151.30. Approximately 2.37 million shares were traded on Friday while an average volume of 2.85 million shares were traded over a 30 day period. The 52-week low of Celgene Corporation (NASDAQ:CELG) shares is $71.23 and its 52-week high is $161.64. The company has a market capitalization of $62.35 billion.

About the company

Celgene Corporation (NASDAQ:CELG) is a global biopharma company. It is primarily involved in discovering, developing and commercializing therapies that are designed to treat cancer & immune-inflammatory-related diseases. Celgene Corporation (NASDAQ:CELG) is involved in the research & development, which is specifically designed to bring ne- therapies to market. The company is also engaged in research for several scientific areas that might deliver therapies and also focus in areas, like intracellular signaling-pathways in cancer & immune cells, immune-modulation in cancer & autoimmune diseases, & therapeutic application of cell-therapies.

The company’s products

Celgene Corporation (NASDAQ:CELG)’s main commercial-stage products include VIDAZA, REVLIMID, ABRAXANE, THALOMID and ISTODAX. Its Additional sources of revenue cover a licensing-agreement with Novartis- this entitles it to various royalties on FOCALIN XR & the entire RITALIN-family of drugs, sale of services via its Cellular Therapeutics subsidiary & other miscellaneous0licensing agreements. In 2012 March it acquired Avila Therapeutics.

Celgene Corporation (NASDAQ:CELG), invests in research &development, & the drug candidates in the company’s pipeline at different stages of preclinical & clinical development. These candidates are pomalidomide & apremilast, its oral anti-cancer & anti-inflammatory agents. Also, PDA-001- the its cellular therapy, oral azacitidine- CC-223 & CC-115 for hematological & solid tumor malignancies, CC-122, the company’s anti-cancer pleiotropic-pathway modifier, and ACE-011 & ACE-536 biological-products used in  anemia in several clinical-settings of unmet need.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.